- -

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma

Mostrar el registro completo del ítem

Ajona, D.; Pajares, MJ.; Chiara, MD.; Rodrigo, JP.; Jantus Lewintre, E.; Camps, C.; Suarez, C.... (2015). Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma. Oral Diseases. 21(7):899-904. doi:10.1111/odi.12363

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/77266

Ficheros en el ítem

Metadatos del ítem

Título: Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma
Autor: Ajona, D. Pajares, M. J. Chiara, M. D. Rodrigo, J. P. Jantus Lewintre, Eloisa Camps, C. Suarez, C. Bagan, J. V. Montuenga, L. M. Pio, R.
Entidad UPV: Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural
Fecha difusión:
Resumen:
OBJECTIVE: Complement C4d-containing fragments have been proposed as diagnostic markers for lung cancer. The purpose of this study was to evaluate the presence of C4d in oropharyngeal (OPSCC) and oral (OSCC) squamous cell ...[+]
Palabras clave: Head and neck cancer , Head and neck cancer,squamous cell carcinoma,oral cancer,biomarker,diagnosis,complement system,C4d,saliva , Squamous cell carcinoma , Oral cancer , Biomarker , Diagnosis , Complement system , C4d , Saliva
Derechos de uso: Cerrado
Fuente:
Oral Diseases. (issn: 1354-523X ) (eissn: 1601-0825 )
DOI: 10.1111/odi.12363
Editorial:
Wiley
Versión del editor: https://dx.doi.org/10.1111/odi.12363
Código del Proyecto:
info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0040/ES/Cáncer/
...[+]
info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0040/ES/Cáncer/
info:eu-repo/grantAgreement/MICINN//PI11%2F00929/ES/Alteraciones genético-moleculares implicadas en el inicio y progresión de los tumores de cabeza y cuello y sus implicaciones clínicas/
info:eu-repo/grantAgreement/MICINN//PI11%2F00618/ES/Papel del sistema del complemento en la progresión tumoral e identificación de marcadores moleculares relacionados su activación/
info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0015/ES/Cáncer/
info:eu-repo/grantAgreement/MINECO//PI13%2F00806/ES/Herramientas moleculares para el análisis pronóstico y la identificación de nuevas dianas terapéuticas en carcinoma no microcítico de pulmón/
info:eu-repo/grantAgreement/MINECO//RD12%2F0036%2F0025/ES/Cáncer/
info:eu-repo/grantAgreement/MINECO//PI14%2F01686/ES/Identificación y validación de marcadores diagnósticos y dianas terapéuticas en cáncer de pulmón relacionados con la activación del sistema del complemento/
[-]
Agradecimientos:
We thank Amaya Lavin for technical assistance. This work was supported by Foundation for Applied Medical Research (FIMA), Red Tematica de Investigacion Cooperativa en Cancer (RD12/0036/0015, RD12/0036/0025, and RD12/0036/0040), ...[+]
Tipo: Artículo

References

Ajona, D., Pajares, M. J., Corrales, L., Perez-Gracia, J. L., Agorreta, J., Lozano, M. D., … Pio, R. (2013). Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. JNCI: Journal of the National Cancer Institute, 105(18), 1385-1393. doi:10.1093/jnci/djt205

Ajona, D., Razquin, C., Pastor, M. D., Pajares, M. J., Garcia, J., Cardenal, F., … Pio, R. (2015). Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLOS ONE, 10(3), e0119878. doi:10.1371/journal.pone.0119878

Arantes, L. M. R. B., de Carvalho, A. C., Melendez, M. E., Carvalho, A. L., & Goloni-Bertollo, E. M. (2014). Methylation as a biomarker for head and neck cancer. Oral Oncology, 50(6), 587-592. doi:10.1016/j.oraloncology.2014.02.015 [+]
Ajona, D., Pajares, M. J., Corrales, L., Perez-Gracia, J. L., Agorreta, J., Lozano, M. D., … Pio, R. (2013). Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. JNCI: Journal of the National Cancer Institute, 105(18), 1385-1393. doi:10.1093/jnci/djt205

Ajona, D., Razquin, C., Pastor, M. D., Pajares, M. J., Garcia, J., Cardenal, F., … Pio, R. (2015). Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer. PLOS ONE, 10(3), e0119878. doi:10.1371/journal.pone.0119878

Arantes, L. M. R. B., de Carvalho, A. C., Melendez, M. E., Carvalho, A. L., & Goloni-Bertollo, E. M. (2014). Methylation as a biomarker for head and neck cancer. Oral Oncology, 50(6), 587-592. doi:10.1016/j.oraloncology.2014.02.015

Bagan, J., Sarrion, G., & Jimenez, Y. (2010). Oral cancer: Clinical features. Oral Oncology, 46(6), 414-417. doi:10.1016/j.oraloncology.2010.03.009

Bell, R. B., Kademani, D., Homer, L., Dierks, E. J., & Potter, B. E. (2007). Tongue Cancer: Is There a Difference in Survival Compared With Other Subsites in the Oral Cavity? Journal of Oral and Maxillofacial Surgery, 65(2), 229-236. doi:10.1016/j.joms.2005.11.094

Bjørge, L., Hakulinen, J., Vintermyr, O. K., Jarva, H., Jensen, T. S., Iversen, O. E., & Meri, S. (2005). Ascitic complement system in ovarian cancer. British Journal of Cancer, 92(5), 895-905. doi:10.1038/sj.bjc.6602334

Blom, A. M., Österborg, A., Mollnes, T. E., & Okroj, M. (2015). Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation. Molecular Immunology, 66(2), 164-170. doi:10.1016/j.molimm.2015.02.029

Brailo, V., Vucicevic-Boras, V., Lukac, J., Biocina-Lukenda, D., Alajbeg-Zilic, I., Milenovic, A., & Balija, M. (2012). Salivary and serum interleukin 1 beta, interleukin 6 and tumor necrosis factor alpha in patients with leukoplakia and oral cancer. Medicina Oral Patología Oral y Cirugia Bucal, e10-e15. doi:10.4317/medoral.17323

Canel, M. (2006). Overexpression of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene Copy Number. Clinical Cancer Research, 12(11), 3272-3279. doi:10.1158/1078-0432.ccr-05-1583

Canel, M., Secades, P., Garzón-Arango, M., Allonca, E., Suarez, C., Serrels, A., … Chiara, M.-D. (2008). Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression. British Journal of Cancer, 98(7), 1274-1284. doi:10.1038/sj.bjc.6604286

Cheng, Y.-S., Rees, T., & Wright, J. (2014). A review of research on salivary biomarkers for oral cancer detection. Clinical and Translational Medicine, 3(1), 3. doi:10.1186/2001-1326-3-3

Corrales, L., Ajona, D., Rafail, S., Lasarte, J. J., Riezu-Boj, J. I., Lambris, J. D., … Pio, R. (2012). Anaphylatoxin C5a Creates a Favorable Microenvironment for Lung Cancer Progression. The Journal of Immunology, 189(9), 4674-4683. doi:10.4049/jimmunol.1201654

Franzmann, E. J., Reategui, E. P., Pedroso, F., Pernas, F. G., Karakullukcu, B. M., Carraway, K. L., … Goodwin, W. J. (2007). Soluble CD44 Is a Potential Marker for the Early Detection of Head and Neck Cancer. Cancer Epidemiology Biomarkers & Prevention, 16(7), 1348-1355. doi:10.1158/1055-9965.epi-06-0011

Hajishengallis, G. (2010). Complement and periodontitis. Biochemical Pharmacology, 80(12), 1992-2001. doi:10.1016/j.bcp.2010.06.017

Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., … Stuart, J. M. (2014). Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. Cell, 158(4), 929-944. doi:10.1016/j.cell.2014.06.049

Hu, S., Arellano, M., Boontheung, P., Wang, J., Zhou, H., Jiang, J., … Wong, D. T. (2008). Salivary Proteomics for Oral Cancer Biomarker Discovery. Clinical Cancer Research, 14(19), 6246-6252. doi:10.1158/1078-0432.ccr-07-5037

De Jong, E. P., Xie, H., Onsongo, G., Stone, M. D., Chen, X.-B., Kooren, J. A., … Griffin, T. J. (2010). Quantitative Proteomics Reveals Myosin and Actin as Promising Saliva Biomarkers for Distinguishing Pre-Malignant and Malignant Oral Lesions. PLoS ONE, 5(6), e11148. doi:10.1371/journal.pone.0011148

Kesselring, R., Thiel, A., Pries, R., Fichtner-Feigl, S., Brunner, S., Seidel, P., … Wollenberg, B. (2014). The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack. European Journal of Cancer, 50(12), 2152-2161. doi:10.1016/j.ejca.2014.05.005

Lingen, M. W. (2010). Screening for Oral Premalignancy and Cancer: What Platform and Which Biomarkers? Cancer Prevention Research, 3(9), 1056-1059. doi:10.1158/1940-6207.capr-10-0173

Liu, C.-J., Lin, S.-C., Yang, C.-C., Cheng, H.-W., & Chang, K.-W. (2011). Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head & Neck, 34(2), 219-224. doi:10.1002/hed.21713

Marimuthu, A., Chavan, S., Sathe, G., Sahasrabuddhe, N. A., Srikanth, S. M., Renuse, S., … Chatterjee, A. (2013). Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1834(11), 2308-2316. doi:10.1016/j.bbapap.2013.04.029

Markiewski, M. M., DeAngelis, R. A., Benencia, F., Ricklin-Lichtsteiner, S. K., Koutoulaki, A., Gerard, C., … Lambris, J. D. (2008). Modulation of the antitumor immune response by complement. Nature Immunology, 9(11), 1225-1235. doi:10.1038/ni.1655

McCormack, S. J., Brazinski, S. E., Jr, J. L. M., Werness, B. A., & Goldstein, D. J. (1997). Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18. Oncogene, 15(3), 265-274. doi:10.1038/sj.onc.1201186

Menéndez, S. T., Rodrigo, J. P., Álvarez-Teijeiro, S., Villaronga, M. Á., Allonca, E., Vallina, A., … García-Pedrero, J. M. (2012). Role of HERG1 potassium channel in both malignant transformation and disease progression in head and neck carcinomas. Modern Pathology, 25(8), 1069-1078. doi:10.1038/modpathol.2012.63

Nitta, H., Wada, Y., Kawano, Y., Murakami, Y., Irie, A., Taniguchi, K., … Imamura, T. (2013). Enhancement of Human Cancer Cell Motility and Invasiveness by Anaphylatoxin C5a via Aberrantly Expressed C5a Receptor (CD88). Clinical Cancer Research, 19(8), 2004-2013. doi:10.1158/1078-0432.ccr-12-1204

NITTA, H., MURAKAMI, Y., WADA, Y., ETO, M., BABA, H., & IMAMURA, T. (2014). Cancer cells release anaphylatoxin C5a from C5 by serine protease to enhance invasiveness. Oncology Reports, 32(4), 1715-1719. doi:10.3892/or.2014.3341

Nunez-Cruz, S., Gimotty, P. A., Guerra, M. W., Connolly, D. C., Wu, Y.-Q., DeAngelis, R. A., … Scholler, N. (2012). Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 14(11), 994-IN1. doi:10.1593/neo.121262

Pajares, M. J., Agorreta, J., Larrayoz, M., Vesin, A., Ezponda, T., Zudaire, I., … Montuenga, L. M. (2012). Expression of Tumor-Derived Vascular Endothelial Growth Factor and Its Receptors Is Associated With Outcome in Early Squamous Cell Carcinoma of the Lung. Journal of Clinical Oncology, 30(10), 1129-1136. doi:10.1200/jco.2011.37.4231

Pardoll, D. (2003). DOES THEIMMUNESYSTEMSEETUMORS ASFOREIGN ORSELF? Annual Review of Immunology, 21(1), 807-839. doi:10.1146/annurev.immunol.21.120601.141135

Park, N. J., Zhou, H., Elashoff, D., Henson, B. S., Kastratovic, D. A., Abemayor, E., & Wong, D. T. (2009). Salivary microRNA: Discovery, Characterization, and Clinical Utility for Oral Cancer Detection. Clinical Cancer Research, 15(17), 5473-5477. doi:10.1158/1078-0432.ccr-09-0736

Pio, R., Corrales, L., & Lambris, J. D. (2013). The Role of Complement in Tumor Growth. Tumor Microenvironment and Cellular Stress, 229-262. doi:10.1007/978-1-4614-5915-6_11

Polanska, H., Raudenska, M., Gumulec, J., Sztalmachova, M., Adam, V., Kizek, R., & Masarik, M. (2014). Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncology, 50(3), 168-177. doi:10.1016/j.oraloncology.2013.12.008

Prasad, G., & McCullough, M. (2013). Chemokines and Cytokines as Salivary Biomarkers for the Early Diagnosis of Oral Cancer. International Journal of Dentistry, 2013, 1-7. doi:10.1155/2013/813756

Ravindranath, N. M. H., & Shuler, C. (2006). Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas. Journal of Oral Pathology and Medicine, 35(9), 560-567. doi:10.1111/j.1600-0714.2006.00466.x

Rhodus, N. L., Ho, V., Miller, C. S., Myers, S., & Ondrey, F. (2005). NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detection and Prevention, 29(1), 42-45. doi:10.1016/j.cdp.2004.10.003

Ricklin, D., Hajishengallis, G., Yang, K., & Lambris, J. D. (2010). Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 11(9), 785-797. doi:10.1038/ni.1923

Rodrigo, J. P., Heideman, D. A. M., García-Pedrero, J. M., Fresno, M. F., Brakenhoff, R. H., Díaz Molina, J. P., … Hermsen, M. A. (2013). Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990-2009). International Journal of Cancer, 134(2), 487-492. doi:10.1002/ijc.28355

Sainger, R. N. S., Shah, M. H., Desai, A. A., Shukla, S. N., Shah, P. M., Telang, S. D., & Patel, P. S. (2006). Clinical Significance of Serum p53 Antibodies in Oral Cancer. Tumori Journal, 92(2), 134-139. doi:10.1177/030089160609200209

Vadrevu, S. K., Chintala, N. K., Sharma, S. K., Sharma, P., Cleveland, C., Riediger, L., … Markiewski, M. M. (2014). Complement C5a Receptor Facilitates Cancer Metastasis by Altering T-Cell Responses in the Metastatic Niche. Cancer Research, 74(13), 3454-3465. doi:10.1158/0008-5472.can-14-0157

Vaezi, A. E., Bepler, G., Bhagwat, N. R., Malysa, A., Rubatt, J. M., Chen, W., … Niedernhofer, L. J. (2014). Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas. Cancer, 120(12), 1898-1907. doi:10.1002/cncr.28643

Van der Waal, I. (2010). Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncology, 46(6), 423-425. doi:10.1016/j.oraloncology.2010.02.016

Yang, Y., Chung, E. K., Zhou, B., Blanchong, C. A., Yu, C. Y., Füst, G., … Varga, L. (2003). Diversity in Intrinsic Strengths of the Human Complement System: Serum C4 Protein Concentrations Correlate with C4 Gene Size and Polygenic Variations, Hemolytic Activities, and Body Mass Index. The Journal of Immunology, 171(5), 2734-2745. doi:10.4049/jimmunol.171.5.2734

Ytting, H., Jensenius, J. C., Christensen, I. J., Thiel, S., & Nielsen, H. J. (2004). Increased activity of the mannan‐binding lectin complement activation pathway in patients with colorectal cancer. Scandinavian Journal of Gastroenterology, 39(7), 674-679. doi:10.1080/00365520410005603

Zimmermann, B. G., & Wong, D. T. (2008). Salivary mRNA targets for cancer diagnostics. Oral Oncology, 44(5), 425-429. doi:10.1016/j.oraloncology.2007.09.009

[-]

recommendations

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem